Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subjects aged ≥18 and ≤60 years and elderly subjects ≥61 years of age.

Trial Profile

Immunogenicity and reactogenicity of the trivalent virosomal influenza vaccine Invivac for the season 2005/2006. An open, baseline controlled study in two groups of healthy subjects: adult subjects aged ≥18 and ≤60 years and elderly subjects ≥61 years of age.

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Influenza virus vaccine liposomal (Primary)
  • Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza B virus infections
  • Focus Pharmacodynamics
  • Acronyms Invivac
  • Sponsors Solvay Pharmaceuticals B.V.
  • Most Recent Events

    • 18 May 2011 New trial record
    • 18 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top